UK medtech needs to seize moment and make most of OLS
This article was originally published in Clinica
Executive Summary
This month’s unveiling of the blueprint for the UK Office for Lifesciences (OLS) will be looked back on as a pivotal moment for the UK healthcare sector, writes Clinica principal analyst Ashley Yeo.